Pfizer/BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose Vaccine Candidate Against COVID-19 and Influenza

Primary tabs

Mon, 2022-12-12 12:59 — mike kraft

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza | BioNTech NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their mRNA-based combination vaccine candidate for influenza and COVID-19, BioNTech

...

A combined vaccine for influenza and COVID-19 has the potential to simplify immunization practices against two severe respiratory diseases caused by evolving viruses that require vaccine adaptation.

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Situation Report

Groups this Group Post belongs to:

- Private group -

Log in or register to post comments

Language

Anonymous's groups in this site

Your groups across all your sites

Recent Content

Recent Comments

Who's online

You are here

Pfizer/BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose Vaccine Candidate Against COVID-19 and Influenza

Primary tabs

User login

Search form

Language

Anonymous's groups in this site

Your groups across all your sites

Recent Content

Recent Comments

Who's online

You are here

Pfizer/BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose Vaccine Candidate Against COVID-19 and Influenza

Primary tabs